Clinical Trial Update: Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two dose regimens of TEV-48125 to placebo for preventive treatment of episodic migraine; results completed with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• TEV-48125

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2018-11-08